Table 1 Baseline characteristics of study population
Control group (n = 25) | Vildagliptin group (n = 25) | P | |
|---|---|---|---|
Mean age (years) | 63.0 ± 10.0 | 64.0 ± 10.1 | 0.81 |
Sex (M/F) | 23/2 | 18/7 | 0.20 |
BMI (kg/m2) | 35 ± 8.3 | 36.4 ± 8.0 | 0.90 |
Diabetes duration (years) | 16.6 ± 10.0 | 23.2 ± 7.0 | 0.20 |
Waist-to-hip ratio | 0.91 ± 0.06 | 0.92 ± 0.09 | 0.74 |
Systolic blood pressure (mmHg) | 137.0 ± 23 | 138.0 ± 17.0 | 0.81 |
Diastolic blood pressure (mmHg) | 80.4 ± 9.3 | 71.3 ± 9.4 | 0.003 |
Heart rate (bpm) | 83 ± 26 | 84 ± 24 | 0.92 |
Risk factors (%) | |||
Dyslipidemia (%) | 16 (64) | 19 (76) | 0.41 |
Retinopathy (%) | 12 (48) | 12 (48) | 1.00 |
Nephropathy (%) | 8 (32) | 6 (24) | 0.71 |
CAD | 5 (20) | 6 (24) | 1.00 |
CVA/tIA | 4 (16) | 3 (12) | 1.00 |
PVD | 8 (32) | 7 (28) | 1.00 |
PVD vascular surgery | 2 (8) | 2 (8) | 1.00 |
Amputation (non-traumatic) | 11 (44) | 11 (44) | 1.00 |
Hypertension | 18 (72) | 19 (76) | 0.70 |
Neuropathy (%) | 17 (68) | 19 (76) | 0.50 |
Alcohol (%) | 7 (28) | 12 (48) | 0.14 |
Smokers (%) | 6 (24) | 6 (24) | 1.00 |
Therapy | |||
Insulin (%) | 17 (68) | 17 (68) | 1.00 |
OHGs | 22 (88) | 19 (76) | 0.50 |
Metformin (%) | 17 (65.4) | 20 (62.5) | |
Gliclazide (%) | 3 (11.5) | 8 (25.0) | |
Dapagliflozin (%) | 6 (23.1) | 4 (12.5) | |